Journal
NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 11, Issue 8, Pages 730-737Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb803
Keywords
-
Funding
- NIDDK NIH HHS [R43-DK063764] Funding Source: Medline
Ask authors/readers for more resources
Obesity and type II diabetes are closely linked metabolic syndromes that afflict > 100 million people worldwide. Although protein tyrosine phosphatase 1B (PTP1B) has emerged as a promising target for the treatment of both syndromes, the discovery of pharmaceutically acceptable inhibitors that bind at the active site remains a substantial challenge. Here we describe the discovery of an allosteric site in PTP1B. Crystal structures of PTP1B in complex with allosteric inhibitors reveal a novel site located similar to 20 Angstrom from the catalytic site. We show that allosteric inhibitors prevent formation of the active form of the enzyme by blocking mobility of the catalytic loop, thereby exploiting a general mechanism used by tyrosine phosphatases. Notably, these inhibitors exhibit selectivity for PTP1B and enhance insulin signaling in cells. Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available